How a key platelet protein (αIIbβ3) turns on and ways to block it
Platelet alphaIIbbeta3 activation and its therapeutic targeting
Researchers are working on drugs that stop a platelet protein from switching on to help people who are at risk of dangerous clots or platelet-related bleeding problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11224898 on NIH RePORTER |
What this research studies
This work looks at how platelets’ important surface protein αIIbβ3 changes shape when it switches from off to on and how new drugs can prevent that switch. Scientists use high-resolution imaging of the full protein in a membrane-like environment to see its shape and how it binds partners. They design small molecule compounds that mimic the normal binding partner to keep the protein locked in a safe state and test these in lab models. Over time the team aims to move promising compounds toward testing in people who need better clot prevention with less bleeding risk.
Who could benefit from this research
Good fit: People with a history of dangerous blood clots, certain platelet function disorders, or those at high risk for thrombosis would be likely candidates for future related trials.
Not a fit: People whose health problems are unrelated to platelet activation or blood clotting are unlikely to benefit from this specific work.
Why it matters
Potential benefit: If successful, this could lead to new medicines that prevent harmful blood clots while reducing the risk of excessive bleeding.
How similar studies have performed: Researchers have already solved structures of the full integrin and developed prototype blocking compounds in the lab, but turning these findings into proven patient treatments is still unproven.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Arnaout, M. Amin — Massachusetts General Hospital
- Study coordinator: Arnaout, M. Amin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.